Why the study?
Does enoxaparin monotherapy reduce recurrent venous thromboembolism or hospital length of stay compared to unfractionated heparin bridged to warfarin in patients with acute symptomatic pulmonary embolism?
Does enoxaparin monotherapy reduce recurrent venous thromboembolism or hospital length of stay compared to unfractionated heparin bridged to warfarin in patients with acute symptomatic pulmonary embolism?
Enoxaparin monotherapy for 3 months is feasible for acute symptomatic pulmonary embolism and significantly reduces hospital length of stay compared to standard heparin-to-warfarin bridging.
No takes yet. Share an insight, caveat, or question.
Supports earlier discharge with enoxaparin monotherapy in acute PE; extends evidence for LMWH feasibility versus heparin-warfarin bridging.
Beckman et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: